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 ABSTRACT   
High throughput somatic mutation screening using formalin-fixed paraffin-embedded  (FFPE) tissues is a major 
challenge due to a lack of established methodology and validated variant calling algorithms.   We aimed to 
develop a targeted sequencing protocol by Fluidigm multiplex PCR and Illumina sequencing, and to establish a 
companion variant calling algorithm.  The experimental protocol and variant calling algorithm were first 
developed and optimised against a series of somatic mutations (147 substitutions, 12 indels ranging 1-33bp ) in 
7 genes, previously detected by Sanger sequencing of DNA from 163 FFPE lymphoma biopsies.   The optimised 
experimental protocol and variant calling algorithm were further ascertained in two separate experiments by 
including the 7 genes as a part of larger gene panels (22 or 15 genes) using FFPE and high molecular weight 
lymphoma DNAs respectively.   We showed that most false positives were due to DNA degradation, deamination 
and Taq polymerase errors, but they were non-reproducible and could be efficiently eliminated by duplicate 
experiments.  A small fraction of false positives appeared in duplicate, but they were at low alternative allele 
frequencies and could be separated from mutations when appropriate threshold value was used.  In conclusion, 
we established a robust practical approach for high throughput mutation screening using archival FFPE tissues. 
 
INTRODUCTION 
  
The advent of next generation sequencing (NGS) technology has transformed the landscape of life science 
research and has led to unprecedented discoveries.  In the field of cancer research, NGS has already uncovered a 
catalogue of extensive somatic mutations and continues to extend this ever growing list of genetic changes in 
human cancer.  In a majority of human malignancies, somatic mutations are found in a wide spectrum of diverse 
oncogenes and tumour suppressor genes at variable frequencies.  For example, in diffuse large B-cell lymphoma 
(DLBCL), somatic mutations are found in more than 300 cancer genes, and on average each lymphoma harbours 
~30 pathogenic mutations.1-4  Most of these pathogenic mutations occur in <20% of cases, but different somatic 
mutations may affect a common molecular pathway.1-4    One of the major challenges is to investigate somatic 
mutations in these newly identified cancer genes, investigate their potential value in diagnosis, prognosis and 
treatment stratification, and translate the relevant research findings into clinical practice using routine formalin 
fixed paraffin embedded (FFPE) diagnostic tissue biopsies.     
 
There are several target enrichment approaches for high throughput mutation screening by NGS, for example, 
hybrid capture with Agilent SureSelect or NimbleGen SeqCap products, and PCR using HaloPlex or RainDance 
technology.   These targeted re-sequencing approaches were originally developed based on high molecular 
weight (HMW) DNA samples and have now  been successfully applied to those from FFPE tissues and circulating 
cell-free tumour DNA.5-7  Several commercial NGS-based assays have been developed for detection of well-
characterised somatic alterations, particularly the hotspot mutations, in cancer genes, and these assays, 
particular those by Ion Torrent, can be applied to a minute amount of DNA extracted from FFPE tissue biopsies.8-
10  Nonetheless, there is no established protocol for discovery research, i.e.  detecting unknown mutations in the 
newly identified cancer genes using FFPE tissue specimens, particularly small biopsies.   Many of the caveats for 
NGS-based mutation screening using FFPE tissue DNA such as artefacts due to poor DNA quality and sequencing 
errors, false negatives due to inadequate target enrichment and suboptimal performance of variant calling 
algorithm, the cut-off value of variant allele frequency for diagnosis of somatic mutation, minimal DNA quantity 
and quality required for successful NGS etc, have not been properly investigated.   
Among  the various target enrichment methods currently available,  PCR using the microfluidic technology 
(Fluidigm Access Array™ System) represents a practical alternative for high throughput mutation screening using 
routine FFPE tissue biopsies.  The Fluidigm Access Array™ System offers several distinct advantages including 1) 
being amenable to small amounts (50ng) of DNA samples; 2) allowing parallel amplification of 48 samples with 
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48 pairs of PCR primers; and 3) offering great flexibility in choice of primers and genetic targets.  The system has 
been successfully used for targeted sequencing using HMW DNA, plasma DNA and very recently FFPE tissue 
DNA.11-13  However, all the caveats as mentioned above, including the strategies to eliminate false positives and 
the cut-off value of variant allele frequency for diagnosis of somatic mutation remain to be established.  In the 
present study, we developed a protocol for high throughput mutation analysis by multiplex PCR with Fluidigm 
Access Array™ System using DNA samples from FFPE tissues, followed by Illumina MiSeq sequencing.  We also 
developed and validated an in-house variant calling algorithm against a wide range of known mutations.  More 
importantly, we have addressed the above issues through a series of designed experiments and data analysis.   
MATERIALS AND METHODS 
 
Tumour materials and DNA extraction:  FFPE lymphoma specimens from 163 cases of DLBCL were retrieved 
from the Haematological Malignancy Diagnostic Service (HMDS) at St James’s University Hospital, Leeds, and 
Addenbrooke’s Hospital, Cambridge.   Local ethical guidelines were followed for the use of archival tissues for 
research with the approval of the ethics committees of the involved institutions. 
 
Haematoxylin and eosin slides were reviewed and crude microdissection was performed in each case to enrich 
tumour cells, ensuring that a tissue area containing >60% of tumour cells was used for DNA extraction.  DNA was 
extracted using the QIAamp DNA Micro Kit (QIAGEN, Crawley, UK) and quantified using Qubit® Fluorometer (Life 
Technologies, UK).  In addition, DNA was extracted from FFPE reactive tonsils, and used for validation of various 
PCR conditions. 
 
Assessment of DNA quality by conventional PCR.   This was performed by PCR of variably sized genomic 
fragments,14 using 2ng template DNA in a 10µl reaction mixture for 40 cycles under a standardised protocol 
(Supplementary Table S1).   
 
Quantification of DNA copy number by real time PCR (qPCR):  This was performed on a Quantstudio 6 
instrument (Life Technologies, UK) using a custom TaqMan® assay of a 195bp fragment of the PPIA gene, which 
was chosen as there is no evidence of PPIA gene copy number change in lymphoma.  Primers and probe were 
designed using the Primer Express software, Version 3.0.1 (Life Technologies, UK).  The sequences of the primers 
(Thermo Scientific, USA) and the probe (Life Technologies, UK) are as follows:  forward primer 5'-
TATGGCTGTCAGGAGCAGTTCTT-3', reverse primer 5'-AAATGGACCAACCTGCTGTCTT-3' and probe 5'-
ACTAAGCAACAAAATAAGCA-VIC-3'.  The qPCR conditions and performance were systematically tested and 
validated prior to data collection.  The real time PCR was performed in a volume of 10μl reaction containing 5μl 
TaqMan® gene expression master mix (Life Technologies, UK), 0.9μl of each primer (900nM final concentration), 
0.25μl of probe (250nM final concentration), 1.95μl PCR certified water (Teknova, UK) and 1μl of template 
genomic DNA.  PCR cycling conditions were: 50°C for 2 minutes, 95°C for 10 minutes and 40 cycles of 95°C for 15 
seconds, 60°C for 1 minute.  For each sample to be quantified, DNA concentration was measured by Qubit 
dsDNA HS assay (Life Technologies, UK) and serial dilutions were performed to give 10ng/μl, 5ng/μl and 2.5ng/μl 
solutions.  A 10-point standard curve with DNA quantity ranging from 10-0.020ng was prepared using high 
quality human genomic DNA (Promega, USA) (Supplementary Figure S1).  TaqMan® qPCR was carried out in a 
batch of 38 DNA samples together with negative control and standard curve in triplicate.  The estimated copy 
number was then calculated and expressed as the % of functional DNA copies relative to the standard curve, 
with an average of the three dilutions taken as the final result (Supplementary Figure S1).  
 
Sanger sequencing:  Mutations in 7 genes including CARD11, CD79A, CD79B, MYD88, TNFAIP3, PRDM1 and TP53 
were first investigated by PCR and Sanger sequencing in 163 DLBCLs using the primers and conditions detailed in 
4 
 
Table S1.   PCR products were routinely sequenced using the BigDye Terminator 3.1 System (Applied Biosystems, 
UK) on an ABI 3730 instrument (Applied Biosystems, UK).  In each case, sequence change was confirmed by at 
least two independent PCR and sequencing experiments.  The somatic nature of mutations was ascertained by 
excluding germline changes through SNP database search and sequencing DNA samples from the microdissected 
normal cells.     
 
PCR product cloning and sequencing:  To confirm mutations that were detected by Illumina MiSeq but not by 
conventional Sanger sequencing, the relevant PCR products were cloned into the pCRTM2.1-TOPO vector 
(Invitrogen) and then transformed into TOP10 competent cells.   Colonies were screened by PCR using vector 
primers and up to 30 positive clones were routinely sequenced by the Sanger method as above.  
 
Primer design and validation for PCR with Fluidigm Access Array:  PCR primer pairs were re-designed for the 
above 7 genes and a further 15 genes using Primer3 (http://frodo.wi.mit.edu) based on hg19 of the human 
genome.  A set of criteria were followed for the primer design and these included: a) targeting a small segment 
of the coding sequence with all amplicons in the range of 144-213bp, thus amenable to DNA samples from FFPE 
tissues; b) covering the entire coding sequence or all the regions known to be mutated in human malignancies; c) 
giving a Tm value at 60±3°C; d) where possible avoiding any known SNPs and GC rich sequence region.  The 
specificity of the primers designed and their potential formation of primer dimers were checked with Primer 
Blast (www.ncbi.nlm.nih.gov/tools/primer-blast/ ), then further assessed by In-Silico PCR 
(http://genome.ucsc.edu/cgi-bin/hgPcr?command=start) and AutoDimer program 
(http://www.cstl.nist.gov/strbase/AutoDimerHomepage/AutoDimerProgramHomepage.htm) (Figure S2).  
 
For each primer pair designed, the forward and reverse primer were tagged with a common sequence 1 (CS1: 5’-
ACACTGACGACATGGTTCTACA-3’) and common sequence 2 (CS2:5’-TACGGTAGCAGAGACTTGGTCT-3’) 
respectively.  All primer pairs were purchased from Thermo Fisher Scientific GmbH and then experimentally 
validated by PCR using DNA samples from FFPE tonsils.  Any primer pairs which failed to yield satisfactory 
amplification of the expected PCR product or gave rise to a non-specific product were redesigned.  In total, 343 
primer pairs for 22 genes were successfully designed and validated, and used for PCR with Fluidigm Access Array 
(Supplementary Table S2).         
 
Preamplification to enrich template target:  For PCR with Fluidigm Access Array using DNA samples from FFPE 
tissues, it was necessary to perform a preamplification with gene specific primers to enrich the template targets 
before PCR with Fluidigm Access Array (Figure 1).  Our initial experiments showed that it was not feasible to 
include all primer pairs in a single preamplification reaction and achieve a uniform amplification of all the targets 
due to overlapping primers and primer dimer interactions.  We then separated the primer pairs that might 
potentially give rise to the above issues based on In-Silico PCR and AutoDimer analyses, and performed two 
separate preamplifications for each sample accordingly.  
 
For each DNA sample, the preamplification and Fluidigm Access Array PCR were performed in duplicate.  The 
preamplification was carried out in a 10μL FastStart High Fidelity Reaction mixture containing 50ng genomic 
DNA from FFPE tissues (or 20ng HMW DNA from fresh frozen tissues), 50nM of each primer, 4.5 mM MgCl2, 5% 
DMSO, 200 μM dNTPs, 1x FastStart High Fidelity Reaction Buffer with MgCI2 and 1U of FastStart High Fidelity 
Enzyme, under the following conditions: 95°C for 10 minutes, 2 cycles of 95°C for 15 seconds and 60°C for 4 
minutes, and 13 cycles of 95°C for 15 seconds and 72°C for 4 minutes.  The preamplified products were routinely 
treated with 4 μL ExoSAP-IT enzyme (Affymetrix, UK) to eliminate the unincorporated primers and dNTPs.  The 
efficacy of preamplification was then validated by conventional PCR (Figure S3A).   
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Massive parallel PCR with Fluidigm Access Array:  This was carried out essentially according to the 
manufacturer's instructions.  Briefly, a sample mixture was prepared by mixing 1µl of the 5-fold diluted pre-
amplified product with 4µl FastStart High Fidelity Reaction Buffer containing 4.5 mM MgCl2, 5% DMSO, 200μM 
each dNTPs, and 0.25U FastStart High Fidelity Enzyme.  Separately, a primer mixture was prepared for each 
primer pair or multiple primer pairs where indicated, with 6μM of each primer and 1x Access Array Loading 
Reagent in a final volume of 50µl.  The Fluidigm 48.48 Access Array was loaded with the sample and primer 
mixtures via the appropriate inlets using an IFC controller.  The array chip was then placed in the Fluidigm 
Thermal Cycler and PCR was performed under the default conditions of the manufacturer (Table S2).  The 
amplified products for each sample were harvested together using an IFC controller.   
 
At the initial stage of the methodology development, the 7 genes were screened for mutations in each of the 
163 lymphoma samples by singleplex PCR with Fluidigm Access Array.   While at the late stage of the 
methodology validation, the 7 genes were included as a part of the 22 genes panel and screened for mutation in 
142 cases of the above lymphoma samples where sufficient DNA was available by multiplex PCR with Fluidigm 
Access Array.  In both experiments, the preamplification and Fluidigm PCR for each DNA sample were carried out 
in duplicate.   
 
In a separate parallel study, the 7 genes were included as a part of the 13 genes panel and screened for 
mutation in 38 cases of splenic marginal zone lymphoma by multiplex PCR with Fluidigm Access Array using high 
molecular weight (HMW) DNA.15  This experiment was similarly carried out in duplicate.   The novel variants 
identified in these samples were further verified by a totally independent experiment.   The sequence data from 
these HMW DNA were analysed in parallel as a comparison.  
 
Barcoding and Illumina MiSeq sequencing:  Barcoding was carried out in a 20μL reaction mixture containing 1μL 
of the 100-fold diluted harvested Fluidigm PCR products and 400nM barcode primers (Fluidigm) in FastStart High 
Fidelity reaction buffer.  The reaction was performed on a conventional PCR thermal cycler under following 
conditions: 95°C for 10 minutes, 15 cycles of 95°C for 15 seconds, 60°C for 30 seconds and 72°C for 1 minute, 
with a completion step at 72°C for 3 minutes. 
 
The barcoded PCR products from various samples were pooled and purified using AMPure XP beads (Beckman 
Coulter, UK) following the manufacturer’s instructions.  A ratio of bead to library at 0.8:1 efficiently removed 
non-specific products, commonly <200 bp (Figure S3D).  Purified PCR product library was quantified using a 
Qubit® Fluorometer.  Purified libraries were routinely sequenced on an Illumina MiSeq sequencer using 250-
base paired-end sequencing protocol. 
 
MiSeq sequence Data analysis: The fastq conversion from BCL and demultiplexing were carried out using the 
MiSeq Reporter software.  The adaptor sequence (TGTAGAACCATGTCGTCAGTGT) was removed using 
cutadapt.16  The reads were aligned to the target sequences using BWA aln and sampe with the “-e 50” 
parameter for the latter.17  The coordinates of the aligned reads were transposed into GRCh37/HG19 
coordinates using an in-house perl program, and transformed to a bam file using samtools.18  Variants were 
identified using an in-house developed variant caller python program, which was specially designed to identify 
variants by Fluidigm PCR and MiSeq sequencing, and systematically validated against a large number of known 
mutations from 7 genes (Figure 2).  The identified variants were annotated using the ensembl human database, 
using the ensembl Variant Effect Predictor,19 and the result was transformed into an excel sheet using a bespoke 
perl script.  After filtering baseline sequence errors and germline changes through SNP database search, novel 
variants seen in both replicates of the same sample were recorded. 
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Sequence search for features potentially associated with false positive variants:  For each type of nucleotide 
substitutions, the 21bp sequence flanking the nucleotide change was extracted. These sequences were aligned 
together and the position weight matrices were calculated and displayed by WebLogo.20  The de novo enriched 
motifs were discovered from these sequences using the MEME suite.21   
 
RESULTS 
 
In the initial study, the experimental protocol and variant calling algorithm were developed and validated 
against the somatic mutations in 7 genes detected by Sanger sequencing of DNA samples from a total of 163 
FFPE diffuse large B-cell lymphoma biopsies.   In the subsequent study, the above optimised experimental 
protocol and variant calling algorithm were tested in two sets of independent experiments with larger panels of 
genes.   
 
1) Development of multiplex PCR with Fluidigm Access Array 
 
As DNA samples from FFPE tissues are highly fragmented and inefficient for direct PCR with Fluidigm Access 
Array, the template targets were first enriched by preamplificaton of each DNA sample with gene specific 
primers.  The major challenges for preamplification are to design primers that can work efficiently in the 
presence of a large number of other primer sets and yield a uniform target enrichment with minimal non-
specific products.  We started with the 7 genes and designed 111 primer pairs, covering 21kb sequence.  Despite 
a meticulous effort in primer design, a uniform target enrichment could not be achieved in a single 
preamplification reaction due to undesired amplification by overlapping primers and poor amplification with a 
small proportion of primer pairs due to primer dimer interaction.  To resolve this, we separated the primer pairs 
that potentially gave rise to these problems into two independent preamplifications based on In-Silico PCR and 
AutoDimer analyses (Figure 1, Figure S2).   The preamplified products were first validated by conventional PCR, 
and then by Fluidigm Access Array PCR and  Illumina MiSeq sequencing (Figure S2).  Illumina MiSeq sequencing 
confirmed adequate depth of read for each of the 111 amplicons.    
 
The standard protocol for Fluidigm Access Array allows PCR with 48 pairs of primers.  To increase capacity, we 
tested a range of multiplex PCR (2-10 primer pairs) with Fluidigm Access Array.  The combination of various 
primer pairs for multiplex PCR was guided by In-Silico PCR and AutoDimer analyses.  Illumina MiSeq sequencing 
of the Fluidigm amplified products showed adequate depth of coverage for each of the amplicons by multiplex 
PCR with up to 4 primer pairs (Figure S4), but unsatisfactory coverage for some of the amplicons by multiplex 
PCR with 5 or more primer pairs.   
 
In addition to the strategies outlined above, a series of quality control measures were established at various 
steps of Fluidigm PCR/MiSeq sequencing including quality control assessment of template DNA, pre-
amplification, Fluidigm PCR, barcode labelling and library purification (Figure S3). 
 
2) Development of strategy and variant calling algorithm for mutation detection 
 
PCR using FFPE DNA is prone to generate sequence errors due to a variety of reasons, such as DNA base 
modification/damage, few copies of intact templates for PCR, Taq polymerase error, etc.  Most of these errors 
are likely to be random, thus not reproducible and could be efficiently eliminated by performing Fluidigm PCR / 
MiSeq sequencing analyses in duplicate.  As expected, the vast majority of these non-reproducible changes were 
found at lower AAF, particularly <10% (Figure 3A).  Nonetheless, a very small fraction of non-reproducible 
changes were seen at much higher AAF, even up to 100% of all reads, indicating errors introduced at the very 
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early steps of the amplification procedure.  The level of these non-reproducible variants was also dependent on 
DNA quality (Figure 3A).      
  
After elimination of non-reproducible changes and SNPs, the remaining variants represented those seen in both 
replicates and were designated as “reproducible variants”.  The absolute number of reproducible changes was 
also much higher at lower AAF (Figure 3A).  However, the percentage of these reproducible variants was minimal 
at lower AAF, but increased steadily at >10% AAF, particularly for HMW DNA, then followed by FFPE tissue DNA 
samples amenable to PCR of 400bp or 300bp.  In contrast, the percentage of reproducible variants was 
consistently low in FFPE tissue DNA samples amenable to PCR of up to 200bp (Figure 3B).  To quantify the 
number of functional copies adequate for PCR, we performed TaqMan real time PCR in a series of representative 
DNA samples (Figure 3C, Figure S1).  This was successful in all HMW and FFPE tissue DNA samples amenable to 
PCR of 300bp or above, but only in 4 of the 7 DNA samples amenable to PCR of up to 200bp.  Of the 4 samples 
amenable to PCR of up to 200bp, which were successfully assayed by TaqMan PCR, the average percentage of 
functional copies was only 1.1% (Figure 3C).    For these reasons, and with further evidence of high baseline 
sequence errors from later analysis, we excluded the DNA samples amenable for PCR of only up to 200bp from 
subsequent mutation analysis.    
 
The reproducible variants at high AAF were likely true genetic changes, while those at lower AAF were probably 
a mixture of false positives and subclonal genetic changes.  To permit comparison of mutations detected 
between Fluidigm PCR / MiSeq sequencing and conventional PCR/Sanger sequencing, we thus initially chose 10% 
AAF as a cut-off value as the variants above this value can be validated by conventional PCR and Sanger 
sequencing, or by cloning and sequencing where necessary.   
 
The reproducible variants with AAF>10% in both replicates were then cross-examined with known somatic 
mutations detected by Sanger sequencing of the 7 genes in a total of 163 DNA samples from FFPE lymphoma 
tissues (Figure 2, Figure S5).  At first, the performance of an in-house variant calling algorithm was assessed and 
"tuned" against 114 known mutations including 106 substitutions and 8 indels (ranging 1-33bp).     While 
assessing the variant calling algorithm, additional novel variants were identified by Fluidigm PCR/MiSeq 
sequencing, and these novel variants were further validated by PCR and Sanger sequencing, or where indicated 
by cloning and sequencing of the PCR products (n=15).   The resulting sequence data were used to further fine-
tune the algorithm, until the algorithm was able to detect all mutations detected or confirmed by Sanger 
sequencing (Figure 2), without both  false negatives and false positives.  Taken together, a total of 159  Sanger 
sequencing confirmed somatic mutations including 147 substitutions and 12 indels (ranging 1-33bp) were used 
to optimise the algorithm.  
 
3) Testing the optimised experimental protocols and variant calling algorithm and determining the cut-off 
value of AAF for somatic mutation detection 
 
To further ascertain the performance of the above optimised experimental protocol and variant calling 
algorithm, we performed the following two sets of independent experiments (Figure 4).   
 
In one set of experiments, the above 111 PCR primer pairs for the 7 genes were further investigated as a part of 
a total of 343 PCR primer pairs for 22 genes covering 65kb sequence using the same cohort of FFPE lymphoma 
DNA samples as above.  These independent experiments confirmed the characteristics of non-reproducible and 
reproducible changes for the 7 genes as presented above, and also showed little difference in these profiles 
between the 7 genes and 15 additional genes.  Cross examination of novel reproducible changes in the 7 genes 
between the two sets of independent experiments showed that the concordance in mutation detection critically 
depended on the cut-off value of AAF (Figure 4B).  With 10% AAF as a cut-off value, a 98.8% concordance was 
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observed, while with cut-off value below 10% AAF, concordances progressively deteriorated, and therefore 
unreliable for mutation detection.    
 
In the other set of experiments, the same 111 PCR primer pairs for the 7 genes were analysed as a part of 157 
PCR primer pairs for 13 genes in an additional cohort of 38 HMW DNA samples from splenic marginal zone 
lymphoma,15 and this experiment was performed twice independently.  Cross examination of novel reproducible 
changes from the 7 genes between the two sets of independent experiments showed 100% concordance at 7% 
AAF or above (Figure 4B).  Thus, the best cut-off value for HMW DNA was defined as 7%.  
 
4) Distinct difference in the nature of false positives between FFPE tissue and HMW DNA  
 
To understand the potential factors underpinning false positives, we examined the nature of non-reproducible 
and reproducible variants in both FFPE tissue and HMW DNA.   Separate analyses of data from the 7 genes and 
others showed no apparent difference and the data were thus combined and presented together.    
 
For non-reproducible changes, there was a broad similarity in the pattern of nucleotide changes between FFPE 
tissue and HMW DNA samples, and both showed frequent C:G>T:A and A:T>G:C alterations, with other base 
changes being at relatively low frequencies (Figure 5).    However, there were marked differences in the 
frequencies of these changes between FFPE tissue and HMW DNA samples, with the frequencies of C:G>T:A 
change being remarkably higher in the FFPE tissue (Figure 5).   There was neither an apparent difference in the 
frequency of indels between FFPE tissue and HMW DNA, nor any association between the nature of non-
reproducible changes and their AAF (Figure S6). 
 
For reproducible changes, we further subdivided them according to the cut-off AAF as those above this value 
were true genetic changes, while those below this value were a mixture of sub-clonal changes and false positives.  
In contrast to non-reproducible changes, the spectrum of the reproducible changes above the cut-off value in 
both FFPE tissue and HMW DNA was broad, without apparent bias toward any particular nucleotide changes 
(Figure 5).   The slightly more variations of the spectrum of the reproducible changes in the HMW group are 
most likely due to a small number (**) of mutations in this group.  
 
Finally, we also searched for sequence features that might be potentially associated with non-reproducible or 
reproducible variants in both FFPE tissue and HMW DNA using the MEME suite,21 but the analyses did not 
identify any sequence features associated with false positives or true mutations.    
 
DISCUSSION  
 
In this study, we have developed and validated a robust high throughput mutation screen using DNA samples 
from archival FFPE tissues.   Experimentally, we have established a practical protocol with various quality control 
steps for multiplex PCR with Fluidigm Access Array, providing a uniform amplification of target genes for Illumina 
MiSeq sequencing.  Bioinformatically, we have generated an in-house variant calling algorithm, and fine-tuned 
its performance against somatic mutations detected by Sanger sequencing.  In addition, we have established a 
strategy to maximally eliminate false positives, enabling detection of known as well as novel mutations.  Our 
study also highlights several critical issues for application of PCR-based target enrichment and next generation 
sequencing to DNA samples from FFPE tissues.      
 
Potential sources of false positives 
 
9 
 
There are many potential causes leading to a false positive sequence change.  Apart from those associated with 
Illumina sequencing, the major causes for false positivity in the context of the current study are poor quality of 
DNA and errors of Taq polymerase.     
 
It is known that poor quality of DNA is prone to PCR and sequencing errors.  We showed in the present study 
that the extent of false positives as measured by non-reproducible changes between the two replicates of the 
same DNA sample depended on DNA quality, with the poorer quality DNA samples displaying higher rates of 
false positives.  The propensity of the DNA samples from FFPE tissues to generate false positives is most likely 
due to DNA damage and few copies of intact templates for PCR.   In comparison with HMW DNA, those from 
FFPE tissues showed a remarkably high incidence of C:G>T:A, accounting for ~40% of non-reproducible changes.  
This extraordinarily high false positive rate is most likely due to deamination of cytosine during tissue formalin 
fixation and storage.13,22,23    
 
Due to degradation, only a small fraction of a DNA sample from FFPE tissue is adequate to serve as templates for 
PCR despite the fact that primers were designed to amplify short fragments (200bp) of genomic sequences.  By 
TaqMan real time PCR, we showed that only 1.1% of genomic DNA from FFPE tissues was adequate for PCR of 
200bp of genomic sequences.  For a DNA sample amenable to conventional PCR of up to 200bp, 50ng DNA 
contains only ~170 functional copies adequate for PCR of 200bp genomic sequences.  As few functional 
templates are available for PCR, any errors introduced at the early steps of the amplification process would 
appear in a substantial proportion of the amplified products.   In line with this,  the other major non-
reproducible changes are  A:T>G:C alterations, which are likely the result of Taq polymerase errors.24 
 
Despite that HMW DNA samples are far better in quality than those from FFPE tissues, these samples also gave 
rise to considerable false positives at low AAF.  In contrast to FFPE tissue DNA, the majority of false positives in 
HMW DNA samples as measured by non-reproducible changes were A:T>G:C changes, being far more frequent 
than C:G>T:A alterations.     
 
Strategies to eliminate false positives 
 
We have established several practical means to eliminate false positives, allowing highly efficient and specific 
detection of somatic mutations.  
 
1) Assessing DNA quality to select those with adequate quality and quantity.  By quality control PCR and further 
supported by TaqMan real time PCR, we found that DNA samples amenable to PCR of 300bp or above were 
adequate for mutation screening with Fluidigm PCR and Illumina MiSeq sequencing.  Under the protocols 
described in this study, 50ng FFPE tissue DNA or 20ng HMW DNA yielded excellent results for sequencing of 343 
amplicons covering 65kb.  However, the amount of template DNA may be subjected to change depending on the 
number of primer pairs used and the size of the amplicons.      
 
2) Investigating each DNA sample in duplicate.  The vast majority of false positives are not reproducible, and 
thus can be efficiently eliminated by analysis of each DNA sample in duplicate.  Under the experimental 
conditions described, duplicate analyses are sufficient and there is no need to further increase the number of 
replicates.  Theoretically, this approach is potentially capable of eliminating all types of random false positives 
resulting from poor quality DNA or Taq polymerase errors.  An alternative approach to reduce false positives is 
treatment of FFPE tissue DNA with uracil glycosylase.13,25  This can significantly reduce false positives resulting 
from deamination of cytosine, however  uracil glycosylase is active only at uracil lesions, but not thymine lesions 
resulting from deamination of 5-methyl cytosine.  In addition, the C:G>T:A artefact at CpG dinucleotides is 
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resistant to uracil glycosylase treatment.25   Thus, duplicate experiments offer broader efficacy in elimination of 
false positives.    
 
3) Choosing appropriate cut-off value of AAF for reliable detection of somatic mutations.  Based on the 
concordance of reproducible variants between two sets of independent experiments, together with known 
somatic mutations by Sanger sequencing, we suggest to use 10% and 7% as the optimal cut-off value of AAF for 
mutation detection in FFPE tissue and HMW DNA respectively.  For detection of well-characterised hotspot 
mutations, it is possible to go below these cut-off values with caution. However, for detection of unknown 
mutations, it is impossible to distinguish somatic mutations from baseline sequence errors when AAF is below 
the cut-off value.  These findings further emphasise the importance of DNA preparation from specimens with 
high tumour cell content, or microdissected tumour cells.       
 
4) A fully validated in-house variant calling algorithm.  This was developed and fine "tuned" by assessing its 
performance on detection of a large number of known somatic mutations including a variety of indels.  We also 
tested this in-house variant calling algorithm in two independent ongoing studies including one on solid tumours 
with different gene panels, and confirmed its excellent performance as judged by correlation with known 
mutations by Sanger sequencing.  In comparison with commercial software, the validated in-house variant 
calling algorithm gave much better performance particularly in indel calling.      
 
Detection of sub-clonal mutations  
 
Based on the above established protocols, Fluidigm PCR and Illumina MiSeq sequencing are much more sensitive 
in somatic mutation screening than conventional Sanger sequencing.  Nearly a third of the mutations 
(45/159=28%) detected by Fluidigm PCR and Illumina MiSeq sequencing were missed by original PCR and Sanger 
sequencing, albeit confirmed by further Sanger sequencing or cloning and sequencing of the PCR products.   In 
line with our findings, Bodor et al also demonstrated an improvement of 39% in mutation detection by amplicon 
based next generation sequencing in comparison with conventional PCR and Sanger sequencing.26  A proportion 
of the somatic mutations additionally detected by Fluidigm /MiSeq sequencing may represent subclonal genetic 
changes.  Nonetheless, subclonal somatic mutations particularly uncharacterised changes at a frequency below 
the cut-off value cannot be reliably identified as these changes are not distinguishable from baseline sequence 
errors despite being technically detectable by the method.  Importantly, it is the cut-off value of AAF, rather 
than the technical sensitivity of the next generation sequencing, which determines how low a subclonal 
mutation can be reliably detected.   
 
In conclusion,  we have established a practical protocol for high throughput mutation analysis using DNA 
samples from archival FFPE tissues by Fluidigm multiplex PCR / Illumina MiSeq sequencing, and an in-house 
variant calling algorithm.   The strategies used to eliminate false positives and identify somatic mutations 
provide a practical solution for high throughput mutation screening using routine FFPE tissue biopsies.    
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Figure 1.  Outline of experimental design for mutation screening using Fluidigm Access Array 
PCR and Illumina MiSeq sequencing.   
Pre-amplification
(reaction A) 
Pre-amplification
(reaction B) 
FFPE tissue DNA 
Fluidigm Access Array PCR 
Barcoding PCR
Library preparation and purification
Illumina MiSeq sequencing 
-- QC step 2
-- QC step 3
-- QC step 4
-- QC step 1 
-- QC step 5
Figure 2.  Strategies for development and improvement of in-house variant calling algorithm.  At 
first, the performance of the in-house variant calling algorithm was assessed and "tuned" against 
114 known mutations by Sanger sequencing.  The additional novel variants identified by Fluidigm 
PCR/MiSeq sequencing were further validated by PCR and Sanger sequencing, where necessary by 
cloning and sequencing of the PCR products.  The resulting sequence data were used to further 
fine-tune the algorithm.  Taken together, a total of 159  Sanger sequencing confirmed somatic 
mutations including 147 substitutions and 12 indels (ranging 1-33bp) were used to optimise the 
algorithm.   
DNA samples with known mutations 
by Sanger sequencing  (n=163)
Fluidigm PCR 
Illumina MiSeq sequencing 
in duplicate
Variant calling by 
In-house algorithm 
Variants reproducible 
in both replicates  
Known mutations in 7 genes by Sanger sequencing 
[ 114 = 106 substitutions + 8 indels ]
tuning  algorithm
Unknown novel variants Sanger sequencing or cloning & Sequencing
Artefacts
Figure 3.   Impact of DNA quality on background noise by Fluidigm Access Array PCR and Illumina MiSeq 
sequencing.   
 
A) The level of both reproducible (seen in both replicates) and non-reproducible (seen only in one 
replicate) variants according to AAF and DNA quality.   FFPE DNA samples are further divided in to 
subgroups according to the size of genomic sequence amenable for amplification by conventional 
multiplex quality control PCR.  The data from FFPE tissue DNA are based on 142 cases investigated by 
two sets of independent experiments (Figure 4) and are shown from one set of the experiments. The 
level of both reproducible and non-reproducible variants, particularly the latter, are remarkably high 
toward lower AAF.  Due to small numbers of data points above 5% AAF, these data are combined and 
presented in groups as indicated. 
  
B) The percentage of reproducible variants of the total (reproducible plus non-reproducible variants) 
according to AAF and DNA quality as above.  Non-reproducible variants are background noise. 
Reproducible variants  at high AAF are likely true mutations, but those at lower AAF are probably a 
mixture of false positives and subclonal genetic changes.  Thus, the proportion of reproducible variants 
could indicate the level of background noise, and a putative threshold level of AAF to be used for 
detection of somatic mutation.  The percentage of reproducible variants critically depends on AAF and 
DNA quality, being minimal at lower AAF, but increasing steadily at >10% AAF in HMW and FFPE tissue 
DNA samples amenable for PCR of ≥300bp genomic fragments, but not in those only supporting PCR of 
up to 200bp.   
  
C)  Quantification of functional copy number of DNA by TaqMan real time PCR.  The level of functional 
copies amenable to PCR critically depends on DNA quality, being 80% in HMW DNA, but only ~1%  in 
DNA samples amplifiable for PCR of up to 200bp.   
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Figure 4:  Determining the cut-off value of AAF for somatic mutation detection.  A) Experimental 
strategy:  two sets of independent experiments were performed  and the reproducible variants 
detected in the 7 genes were cross validated, together with the known mutations by Sanger sequencing.  
B) Comparison of the reproducible variants from the 7 genes between the two independent 
experiments shows that the concordances critically depend on the level of AAF.     For DNA samples 
from FFPE tissues, a cut-off value of ≥10% AAF yields 98.8% concordance, while for HMW DNA, the cut-
off value can be as low as ≥7% AAF, generating 100% concordance.  
FFPE tissue DNA  HMW DNA  
Reproducible variants detected in both independent experiments at the indicated AAF; 
Reproducible variants detected in one experiment at the indicated AAF, and in the other independent 
experiment at slightly lower AAF.  
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Figure 5:  The nature of non-reproducible and novel reproducible changes in FFPE tissue and HMW DNA 
samples.  For non-reproducible changes, there are marked differences in the frequencies of base changes 
between FFPE tissue and HMW DNA samples, with the frequencies of  C:G>T:A change being remarkably  
higher in the FFPE tissue DNA.  For novel reproducible changes, the spectrum of base changes between FFPE 
tissue and HMW DNA is similar, being broad without major bias toward any particular changes.  
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Figure S1.  Quantification of functional copies of DNA by TaqMan real time PCR.  
 
A) Standard curve.  High quality human genomic DNA (Promega) was serially diluted, and input 
DNA ranging from 10ng to 0.020ng was quantified in triplicate by TaqMan real time PCR of a 
195bp fragment of the PPIA  gene to generate a standard curve. 
 
B)  Example of TaqMan real time PCR.  For each sample, input DNA of 10ng, 5ng and 2.5ng was 
quantified  in triplicate as above.  The average estimated % of functional copy number relative 
to the standard curve was then calculated. 
 
10ng 
 
5ng 
 
2.5ng 
 
10ng 
 
5ng 
 
2.5ng 
HMW 
FFPE 
Sequence lineup Matches Score 
22 22 
No. of amplicons Size (bp) % 
Target 56 151-203  64.4% 
Undesired 
amplification 
1 25 1.1% 
30 362-599  34.5% 
1F 
1R 
2F 
2R 
Undesired amplification 
No. of amplicons Size (bp) % 
Target 111 140-203 48.1% 
Undesired 
amplification 
70 25-139 30.3% 
50 223-300 21.6% 
Analysis of 111 primer pairs for 7 genes 
No. of amplicons Size (bp) % 
Target 55 148-211  66.3% 
Undesired 
amplification 
1 49 1.2% 
27 328-598  32.5% 
Reaction A Reaction B 
Stratification according to In-Silico PCR analysis 
A 
B 1F 
1R 
2F 
2R 
Primer dimer 
PRDM1 exon 6  
3F 
3R 
PRDM1_ex6r_3F  
PRDM1_ex6r_1R 
200bp 
250bp 
100bp 
200bp 
250bp 
100bp 
Stratification according to AutoDimer analysis 
Reaction A Reaction B 
PRDM1_ex6r_1 PRDM1_ex6r_3 
200bp 
250bp 
100bp 
PRDM1_ex6r_1 PRDM1_ex6r_3 
Figure S2.  Stratification of PCR primer pairs for different pre-amplification reactions and multiplex PCR by In-Silico PCR and 
AutoDimer analysis. 
A. In-Silico PCR analysis allows identification of primer pairs that give rise to undesired and non-specific amplification, and  
stratification of them in separate preamplification and multiplex PCR reactions.  For example, analysis of the 111 primer pairs 
for the 7 gene panel  identifies a number of putative undesired amplifications largely due to  overlapping primers.  The  large 
sized putative undesired amplification (>300bp) are normally not amplified under the experimental conditions used and thus 
do not impose any problem.  However, the small sized undesired amplifications are seen experimentally and these undesired 
amplifications cause failure of amplification of a proportion of primer pairs in Fluidigm Access Array PCR.  These undesired 
amplifications can be efficiently prevented by placing the relevant primer pairs in different preamplification reactions as 
guided by In-Silico PCR analysis.  After purification, the two separate preamplified products can then be pooled and used as 
template for multiplex PCR with Fluidigm Access Array.  
B. AutoDimer analysis identifies primers potentially interacting with each other.  Any primers with an AutoDimer score above 
12 should be placed in separate reactions.  As shown here, PRDM1_ex6r_3 and PRDM1_ex6r_1  have a high degree of 
complementary sequences and prevent amplification of the targeted sequences when present together. By separating them 
into two separate reactions, both targeted genomic fragments can be efficiently amplified. PCR products were run on 10% 
PAGE gel.  
AutoDimer analysis 
Figure S3. Quality control at various steps of Fluidigm Access Array PCR and Illumina MiSeq sequencing.  
QC step 1:  Assessment of preamplified products by conventional 
multiplex PCR and 10% polyacrylamide gel electrophoresis.   
1µl of 5-fold diluted pre-amplified product was amplified with 3-4 
primers pairs grouped based on  In-Silico PCR and AutoDimer 
analyses.  PCR was carried out in a 5µl reaction mixture containing 
4.5mM MgCl2, 5% DMSO, 200μM each dNTPs, 1.5μM of each 
primer, and 0.25U FastStart High Fidelity Enzyme Blend.  The PCR 
conditions are identical to those used for Fluidigm Access Array 
(Table S2).  Lanes 1-7: representative samples; Lane 8: negative 
control from preamplification  reaction without template DNA. 
 
QC step 2:  Assessment  of Fluidigm Access Array PCR products by 
2%  agarose gel electrophoresis.  Lane 1:  a negative control went 
through preamplification and Fluidigm PCR;  Lanes 2-8: individual 
samples. 
 
QC step 3:  Assessment of barcoded PCR products by 2% agarose 
gel electrophoresis.  Lanes 1-7: individual samples;  Lane 8:  a 
negative control went through preamplification, Fluidigm PCR 
and barcoding.  
QC step 4:  Assessment of library 
purification.  Left panel: optimisation 
of AMPure XP beads:sample volume 
ratio using DNA ladder and the ratio 
at 0.8 gives the best purification, 
effectively removing DNA fragments 
<200bp.  Right panel:  The barcoded 
PCR products from various samples 
were pooled and purified as above.  
U:  un-purified product;  P: purified 
product.   
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Figure S4.  Examples of depth of coverage by Fluidigm Access Array PCR and Illumina MiSeq sequencing.  
Adequate depth of coverage can be achieved for each of the amplicons by multiplex Fluidigm Access 
Array PCR with up to 4 primer pairs.   AVG: average.       
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Substitution:  
L0092  
TNFAIP3  
c.589G>T 
Insertion:  
L0092  
TNFAIP3  
c.923 T>TAA 
Deletion:  
L0112  
TNFAIP3 
c.973 TTAAA>T 
Figure S5. Examples of somatic mutations detected by Fluidigm Access Array PCR and Illumina 
MiSeq sequencing. 
Figure S6.  The nature of non-reproducible variants is independent of AAF. 
FFPE tissue DNA  
0
10
20
30
40
50
60
70
80
A:T>C:G A:T>G:C A:T>T:A C:G>T:A C:G>G:C C:G>A:T Indels
%
 to
ta
l v
ar
ia
nt
s
Variant change
1-5% AAF
6-10% AAF
11-50% AAF
51-100% AAF
